Celcuity (CELC) Stock Price
Celcuity Price
Analysts set a median price target of 155.00 USD, implying 95.3% above the current price. Of 18 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 76% above its 52-week low.
Celcuity stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Celcuity over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Celcuity stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Celcuity's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Celcuity Price |
|---|---|
| 9/24/2026 | 79.37 USD |
| 9/22/2026 | 84.15 USD |
| 9/21/2026 | 82.96 USD |
| 9/18/2026 | 83.85 USD |
| 9/17/2026 | 84.91 USD |
| 9/16/2026 | 82.79 USD |
| 9/15/2026 | 80.83 USD |
| 9/14/2026 | 83.12 USD |
| 9/11/2026 | 83.54 USD |
| 9/10/2026 | 85.49 USD |
| 9/9/2026 | 90.08 USD |
| 9/8/2026 | 96.03 USD |
| 9/4/2026 | 95.70 USD |
| 9/3/2026 | 96.43 USD |
| 9/2/2026 | 96.20 USD |
| 9/1/2026 | 91.98 USD |
| 8/31/2026 | 89.06 USD |
| 8/30/2026 | 88.73 USD |
| 8/28/2026 | 89.14 USD |
| 8/27/2026 | 94.09 USD |
| 8/26/2026 | 95.08 USD |
| 8/25/2026 | 92.27 USD |
| 8/24/2026 | 91.57 USD |
| 8/21/2026 | 93.53 USD |
| 8/20/2026 | 90.57 USD |
| 8/19/2026 | 92.20 USD |
| 8/18/2026 | 91.64 USD |
| 8/14/2026 | 92.00 USD |
| 8/13/2026 | 86.60 USD |
| 8/12/2026 | 90.26 USD |
Celcuity Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Celcuity Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | 0.04 | 0.37 | 0.78 | 1.25 | 1.75 |
| – | – | – | – | – | – | – | – | – | – | – | – | 876.32 | 110.24 | 60.77 | 39.71 |
| -2.00 | -3.00 | -5.00 | -7.00 | -7.00 | -9.00 | -28.00 | -39.00 | -66.00 | -113.00 | -172.00 | -241.00 | 12.00 | 237.00 | 467.00 | 729.00 |
| – | – | – | – | – | – | – | – | – | – | – | -634.21 | 3.23 | 30.38 | 37.24 | 41.61 |
| -2.00 | -3.00 | -6.00 | -7.00 | -7.00 | -9.00 | -29.00 | -40.00 | -63.00 | -111.00 | -177.00 | -191.00 | -58.00 | 107.00 | 270.00 | 426.00 |
| – | 50.00 | 100.00 | 16.67 | – | 28.57 | 222.22 | 37.93 | 57.50 | 76.19 | 59.46 | 7.91 | -69.63 | -284.48 | 152.34 | 57.78 |
| 6.00 | 6.72 | 10.08 | 10.16 | 10.25 | 10.28 | 14.91 | 16.87 | 28.90 | 42.87 | 52.54 | 52.54 | 52.54 | 52.54 | 52.54 | 52.54 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Celcuity generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Celcuity retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Celcuity's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Celcuity has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Celcuity's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Celcuity stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Celcuity Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Celcuity business model & stock analysis
Celcuity SWOT Analysis
Strengths
Celcuity Inc possesses several strengths that contribute to its competitive advantage in the market:
- Cutting-edge technology and innovative solutions
- Strong intellectual property portfolio
- Highly skilled and experienced research and development team
- Strong relationships with key industry partners
- Solid financial position and strong revenue growth
Weaknesses
Despite its strengths, Celcuity Inc also has certain weaknesses that can impact its performance:
- Relatively small size compared to established competitors
- Limited brand recognition in the market
- Dependency on a few key customers
- Limited marketing and distribution capabilities
- Risk of potential regulatory challenges
Opportunities
Celcuity Inc can capitalize on the following opportunities to further expand and develop its business:
- Growing demand for personalized medicine and targeted therapies
- Increase in healthcare spending and focus on precision oncology
- Expansion into new geographic markets
- Potential collaborations and partnerships with pharmaceutical companies
- Advancements in technology and data analytics
Threats
Celcuity Inc faces the following threats that may hinder its growth and success:
- Intense competition from established players in the industry
- Fast-paced technological advancements and potential disruption
- Stringent regulations and compliance requirements
- Economic fluctuations and market uncertainties
- Potential intellectual property disputes and legal challenges
Celcuity Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Celcuity Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Celcuity historical P/E ratio, EBIT multiple, and P/S ratio
Celcuity annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Celcuity's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Celcuity's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Celcuity's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Celcuity shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Celcuity forecasts and price targets in September 2026
Analyst Price Targets 2026Celcuity Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/17/2026 | Maintained | Buy | 39 | |
| 8/17/2026 | Maintained | Market Outperform | – | |
| 8/14/2026 | Maintained | Buy | 57 | |
| 8/14/2026 | Maintained | Buy | 58 | |
| 8/14/2026 | Maintained | Buy | – | |
| 7/15/2026 | Maintained | Buy | – | |
| 7/15/2026 | Maintained | Market Outperform | – | |
| 6/3/2026 | Maintained | Overweight | 58 | |
| 6/3/2026 | Maintained | Buy | – | |
| 6/3/2026 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Celcuity Earnings Calls
Celcuity Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/11/2026 | -1.45USD | - | 3.99 MUSD | - | 2026 Q3 |
| 8/13/2026 | -1.16USD | -1.44USD | 4.42 MUSD | - | 2026 Q2 |
| 5/14/2026 | -1.04USD | -0.97USD | 2.94 MUSD | - | 2026 Q1 |
| 3/25/2026 | -1.06USD | -0.97USD | 1.28 MUSD | - | 2025 Q4 |
| 11/12/2025 | -1.02USD | -0.92USD | -USD | - | 2025 Q3 |
| 8/14/2025 | -0.90USD | -1.04USD | -USD | - | 2025 Q2 |
| 3/31/2025 | -0.72USD | -0.85USD | -USD | - | 2025 Q1 |
| 11/14/2024 | -0.65USD | -0.70USD | -USD | - | 2024 Q3 |
| 8/14/2024 | -0.71USD | -0.62USD | -USD | - | 2024 Q2 |
| 5/15/2024 | -0.71USD | -0.64USD | -USD | - | 2024 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Celcuity stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Celcuity shareholder structure
| % | Name |
|---|---|
20.06568% | |
20.06568% | |
8.55526% | |
8.01077% | |
7.92712% | |
7.88633% |
Celcuity Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ |
Celcuity Executives and Management Board
10 members · avg. age 68 · 30 % women
Mr. Brian Sullivan (63)
Chairman of the Board, Chief Executive Officer, Co-Founder · since 2012
6.59 M USD
Management
Dr. Lance Laing (63)
Co-Founder, Chief Science Officer, Vice President, Secretary, Director · since 2012
Ms. Vicky Hahne (58)
Chief Financial Officer
Dr. Charlotte Moser
Chief Medical Officer
Board of Directors
Dr. Richard Buller (75)
Independent Director
Mr. David Dalvey (66)
Independent Director
Dr. Leo Furcht (78)
Independent Director
Dr. Polly Murphy (60)
Independent Director
Mr. Richard Nigon (77)
Independent Director
Mr. Charles Romp
Independent Director
Celcuity Supply Chain
Celcuity Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.66 | 0.66 | 0.68 | ||
| 2 | 0.90 | 0.74 | 0.67 | ||
| 3 | 0.92 | 0.56 | 0.57 | ||
| 4 | -0.06 | 0.56 | 0.56 | ||
| 5 | 0.82 | 0 | 0.30 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.04 | -0.41 | -0.07 | ||
| 2 | 0.73 | -0.26 | 0.17 | ||
| 3 | 0.50 | 0.93 | 0.17 |
Frequently asked questions about Celcuity
Celcuity Inc, a targeted diagnostics company, operates on a unique business model focusing on developing and commercializing novel companion diagnostic tests. By analyzing a patient's living cancer cells used in diagnostic testing, Celcuity gathers crucial data to identify abnormal signaling pathways that can guide physicians in selecting the most effective treatment. Leveraging its proprietary CELsignia platform, Celcuity aims to improve patient outcomes by enabling the identification of patients who are likely to respond favorably to specific targeted therapies. Through its innovative approach, Celcuity strives to revolutionize personalized medicine in the field of cancer diagnostics.
Celcuity Inc is primarily active in the biotechnology industry.
The main competitors of Celcuity Inc in the market are large pharmaceutical companies such as Pfizer, Novartis, and Roche.
Celcuity Inc is a biotechnology company based in Minneapolis, Minnesota. Founded in 2012, Celcuity focuses on developing innovative therapeutic solutions for the treatment of cancer. The company specializes in discovering cancer subtypes by analyzing a patient's cells to identify abnormal signaling activity. By providing this personalized information, Celcuity aims to help healthcare professionals make more informed treatment decisions. With its cutting-edge platform and collaborations with renowned institutions, Celcuity Inc is committed to advancing precision medicine and improving patient outcomes in the field of oncology.
Celcuity Inc has achieved several significant milestones in its journey. The company has made remarkable progress in the field of precision medicine and oncology diagnostics. One of the notable achievements includes its successful initial public offering (IPO), which helped to raise funds for further research and development efforts. Moreover, Celcuity has successfully established collaborations with renowned academic institutions and pharmaceutical companies, allowing for the expansion of its product pipeline and access to a broader patient population. The continued advancements in their proprietary CELsignia platform have also provided valuable insights into the molecular signatures of various cancers, enhancing physicians' ability to personalize treatment strategies.
Celcuity Inc is primarily present in the United States.
Celcuity Inc represents the values of innovation, precision, and patient-centered care. As a biotechnology company, Celcuity is dedicated to developing and commercializing novel diagnostic tests to identify and treat cancer patients who can benefit from targeted therapies. Their corporate philosophy emphasizes the importance of using cutting-edge technology to improve patient outcomes and provide physicians with precise and actionable information. By harnessing the power of CELsignaling™, Celcuity strives to revolutionize therapeutic decision-making in oncology. Through their relentless pursuit of scientific advancements, Celcuity Inc aims to make a significant and positive impact in the field of precision medicine.
Analysts currently set an average price target of 154.33 USD for the Celcuity stock (median: 155.00 USD), implying +92.9 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Celcuity stock: 17 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Celcuity to generate revenue of 35.61 M USD and earnings per share of -3.65 USD.
Converted at the current exchange rate, the Celcuity share trades at 69.74 EUR (79.37 USD).
The Celcuity share (CELC) is listed on 1 stock exchanges, including: NASDAQ (CELC).
Celcuity Inc is a US biotechnology company specializing in the development of precision medicine solutions for the treatment of cancer. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota. Celcuity operates in two business areas: drug development and diagnostic test development. Celcuity's drug development is based on the discovery of new mechanistic target molecules that play a role in cancer formation. The company is working intensively to develop drugs that specifically target these targets to achieve better efficacy and tolerability in cancer therapy. The second business area is the development of diagnostic tests. Celcuity has developed a novel diagnostic procedure that identifies the molecular signature of cancer cells, enabling rapid and targeted diagnosis. These tests can help identify patient groups most likely to benefit from specific cancer treatments, leading to better and personalized therapies. Celcuity already offers various diagnostic tests, including the CELx HER2 Signaling Function Test, which measures the HER2 signaling pathway in tumor cells, allowing prediction of the efficacy of various HER2-targeted therapies. Celcuity's business model is based on the development of innovative solutions based on precision medicine approaches. The company collaborates with renowned research institutions and pharmaceutical companies. Celcuity is a publicly traded company financed through the sale of shares. The company has invested significantly in research and development in recent years and has acquired several patents to protect its technology. Celcuity aims to improve the lives of cancer patients through the development of better treatment options and a personalized approach. Collaboration with the medical community and the development of innovative diagnostic tests are key priorities. Overall, Celcuity is a promising biotechnology company leading in the field of precision medicine for cancer therapy. The company has made significant progress in recent years and is committed to revolutionizing cancer therapy through the provision of personalized treatments.
The expected revenue of Celcuity is 35.61 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Celcuity is -191.95 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Celcuity is currently -21.72. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Celcuity stock.
The price-to-sales ratio (P/S) of Celcuity is currently 117.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Celcuity stock.
The Eulerpool Quality Score for Celcuity is 4/10.
The ISIN of Celcuity is US15102K1007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Celcuity is A2JAAX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Celcuity is CELC. The ticker symbol is used to trade Celcuity shares on the stock exchange.
Celcuity paid dividends every year for the past 0 years.
Celcuity is assigned to the 'Health' sector.
The dividends of Celcuity are distributed in USD.
Celcuity stock
Celcuity Peer Group
Celcuity Ticker
Celcuity FIGI
All fundamentals and in-depth analysis of Celcuity
Our stock analysis for Celcuity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celcuity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.